24 August, 2016 by The TZ Newswire Staff Comments Off on Venezuela-based Bitcoin Brokerage Cryptobuyer Adds Dash Support
Venezuela-based Bitcoin Brokerage Cryptobuyer Adds Dash Support
Can Dash, the cryptocurrency formerly known as DarkCoin, help Venezuelans protect their money in the face of the economic crisis?
24 August, 2016 by The TZ Newswire Staff Comments Off on More millennials are giving back to the ‘Bank of Mom and Dad’
More millennials are giving back to the ‘Bank of Mom and Dad’
Nearly 20 percent of millennials are financially supporting a parent. Here’s how to plan for that commitment.
24 August, 2016 by The TZ Newswire Staff Comments Off on Powerful earthquake strikes central Myanmar, rattles region
Powerful earthquake strikes central Myanmar, rattles region
A powerful earthquake of 6.8 magnitude struck central Myanmar on Wednesday.
24 August, 2016 by The TZ Newswire Staff Comments Off on Some key financial questions for 30-something savers
Some key financial questions for 30-something savers
If those age 30-plus can’t answer these questions about earning, saving and spending, their finances need attention.
24 August, 2016 by The TZ Newswire Staff Comments Off on China P2P Lending Rules Said to Include Caps on Amount Borrowed
China P2P Lending Rules Said to Include Caps on Amount Borrowed
A report in ChinaNews is saying The China Banking Regulatory Commission (CBRC), along with partner agencies, will release rules regarding online lending that will include lending caps. According to the report, individuals will be able to borrow up to 200,000 CNY (USD $30,000) from any… Read More
24 August, 2016 by The TZ Newswire Staff Comments Off on Stocks Keeps Rallying, but Investors are Buying Bonds Instead
Stocks Keeps Rallying, but Investors are Buying Bonds Instead
The SPDR S&P 500 ETF Trust (NYSE:SPY) is set to open at a new all-time high this morning, yet th
24 August, 2016 by The TZ Newswire Staff Comments Off on Why You Should (and Shouldn’t) Buy Gilead Sciences, Inc.
Why You Should (and Shouldn’t) Buy Gilead Sciences, Inc.
Image Source: Getty Images.
The declining sales of Gilead Sciences‘ (NASDAQ: GILD) groundbreaking hepatitis C medicine Harvoni have turned this once high-flying biotech into a battleground stock. And so far, the bears are winning in a landslide, with Gilead shedding a quarter of its value since the start of 2016.